A Conversation with Jim Greenwood – BIO CEO and President

The newly passed legislation in Congress that will reform FDA and reauthorize the Prescription Drug User Fee Act for another five years is just one example of dynamic change that is occurring in the marketplace. 

James_c1_greenwood_highresThis week, I was able to speak with Jim Greenwood, President and CEO of BIO,(representing over 1100 biotechnology companies) to talk about the impact of the reforms – what went into them, and what did not (i.e., a regulatory pathway for follow-on biologics).   We also discussed public perceptions of drug safety standards and how the COX-2 safety scares have shaped the public and policy maker psyche.  Lastly, we discussed how the struggling image of the medicines industry affects public policy outcomes. 

Mr. Greenwood represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005 where he served as a senior member of the Energy and Commerce Committee.  From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee’s vast jurisdiction.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in Podcast. Bookmark the permalink.

Comments are closed.